Plasmalyte A

Phase 3Small molecule

AAsklepion Pharmaceuticals, LLC

Plasmalyte A is one of 94 small molecule programs targeting Ischemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

IschemiaActive, not recruiting

Acute Lung InjuryActive, not recruiting

OsteoarthritisActive, not recruiting

IschemiaPhase 1/Phase 2

Active, not recruiting

Acute Lung InjuryPhase 3

Active, not recruiting

OsteoarthritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Plasmalyte A

AAsklepion Pharmaceuticals, LLC

Phase 3

2 2

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 3

Toradol

Roche

Preclinical

1 4

Bayer Aspirin

Cataflam

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 7

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 8

Chirocaine

PPurdue Pharma LP

Preclinical

1 9

Lunesta

Akero Therapeutics

Preclinical

1 10

Benadryl

PParkedale

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoarthritis2 trials

Allogeneic Mesenchymal Stem Cells in Osteoarthritis

Completed·SStempeutics Research Pvt Ltd·Phase 2·NCT01453738·60 enrolled

Allogeneic Mesenchymal Stem Cells for Osteoarthritis

Completed·SStempeutics Research Pvt Ltd·Phase 2·NCT01448434·72 enrolled

Ischemia1 trial

Mesenchymal Stem Cells in Critical Limb Ischemia

Completed·SStempeutics Research Pvt Ltd·Phase 1/2·NCT00883870·20 enrolled

Bone1 trial

Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI

Completed·SStempeutics Research Pvt Ltd·Phase 1/2·NCT00883727·20 enrolled

Acute Lung Injury1 trial

A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

Terminated·AAsklepion Pharmaceuticals, LLC·Phase 3·NCT05253209·64 enrolled

Cardiopulmonary Bypass1 trial

Comparative Analysis Between Ringer's Lactate vs Plasma Lyte-A as Cardiopulmonary Bypass Prime

Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT03043131·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Plasmalyte A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plasmalyte A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plasmalyte A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Asklepion Pharmaceuticals, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAsklepion Pharmaceuticals, LLC

Plasmalyte A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteoarthritis2 trials

Ischemia1 trial

Bone1 trial

Acute Lung Injury1 trial

Cardiopulmonary Bypass1 trial

References

Drug Info

Quick Facts

Related News